Type 1 diabetes is caused by T cell-mediated autoimmune destruction of insulin-producing cells in the pancreas. Until now insulin replacement is still the major therapy, because islet transplantation has been limited by donor availability and by the need for long-term immunosuppression. Induced islet neogenesis by gene transfer of Neuogenin3 (Ngn3), the islet lineage-defining specific transcription factor and Betacellulin (Btc), an islet growth factor has the potential to cure type 1 diabetes. Adenoviral vectors (Ads) are highly efficient gene transfer vector; however, early generation Ads have several disadvantages for in vivo use. Helper-dependent Ads (HDAds) are the most advanced Ads that were developed to improve the safety profile of early generation of Ads and to prolong transgene expression 1 . They lack chronic toxicity because they lack viral coding sequences 2-5 and retain only Ad cis elements necessary for vector replication and packaging. This allows cloning of up to 36 kb genes.
1. Clone mouse Ngn3 and Btc cDNAs into the pLPBL1 plasmid vector that contains a ubiquitous elongation factor-1 promoter (BOS) and a poly A signal. Upon completion, verify vectors by sequence analysis and then subclone these expression cassettes into pΔ28 HDAd shuttle plasmid 6 . 2. Digest HDAd shuttle vectors by PmeI to release the plasmid backbone, purify DNAs by phenol/chloroform/isoamyl alcohol extraction followed by ethanol precipitation and reconstitute with transfection-grade water.
Preparation of STZ:
Prepare 0.1M citrate buffer, and adjust PH to 4.3-4.5. Filter this through a 0.22 mm syringe filter. Using sterile water dilute this to 0.01 M Na Citrate pH 4.2-4.5. Dissolve appropriate amount of STZ (Sigma) in this solution to achieve a final concentration of 12.5 mg/ml. At this concentration there is no precipitation. Keep this STZ solution at 4 °C till used. Bring the temperature of the injecting solution to room temperature immediately prior to injection. The STZ solution should be prepared fresh each day and injected within 5-10 min of being dissolved. 2. Inject this STZ solution intraperitoneally (10 μl/gm to achieve a dose of 125 μg/g body weight), in the evening between 5-7 pm (before the lights are turned off in the mouse facility and the mice start feeding actively), on two consecutive days 9 .
Monitoring mice glucose and injection of HDAd vectors.
1. Fast mice for 6 hr and measure body weight and blood glucose weekly until mice have hyperglycemia (≥250mg/dl). Use a One Touch glucometer for blood collected by tail snip. Once blood glucose is ≥250 mg/dl, recheck the blood glucose again in 48 hr after a 6 hr fast to ensure persistent hyperglycemia and blood glucose is within the target range for treatment: 250-500 mg/dl. G needle and 1 ml syringe). Insert needle and inject the vector slowly. If the needle is in the vein, a flash of blood may be seen in the hub of the needle and also there is no resistance during injection. After removing the needle, hold the injection site with gauze to stop bleeding before returning mice to cage. If the needle is not in the vein there is significant resistance to injection and a little subcutaneous wheal arises. At this time remove the needle and try again at a different site.
Analysis of effects of HDAd-Ngn3+HDAd-Btc treatment.
1. Monitor 6 hr fasting glucose and body weight weekly after vector treatment. 2. Collect blood from the saphenous vein or tail vein in the leg every 2 weeks to assay insulin (Mouse Insulin ELISA kit, Mercodia) and liver enzymes (AST and ALT Infinity Reagents, Thermo Scientific) using commercial kits. 1. Place the mouse in an uncapped 50 ml Falcon tube with holes made in the closed end. 2. The mouse's head is at the closed end of the tube and legs and tail at the open side of the tube. To collect blood from the left leg, extend the left leg outside of the tube and gently pinch the skin of the thigh between the thumb and forefinger to immobilize the leg. 3. Use a shaver to remove the hair from the shin/lower leg area, to expose the saphenous vein, which is present on the lateral side of the lower leg. Clean the shaved skin with 70% alcohol and let it dry. 4. Puncture the saphenous vein with a 25 gauge needle, Collect the blood with Microvette CB300 tube (Sarstedt) and put the tubes on the ice. 5. Press the puncture site with gauze to stop bleeding before returning the mice to the cages. 6. Centrifuge the tubes at 3,000 x g for 5 min, take the supernatant and store at -20 °C for further analysis.
Perform glucose tolerance test (GTT) at 6 weeks after treatment.
1. Dissolved D-glucose (Sigma) in distilled water to make 15% glucose (15 g / 100 ml) and sterile filter the glucose. 2. Fast mice for 6 hr. Use warm pad to warm the mice and collect the blood (0 min time point). Then inject 1.5 g/kg of D-Glucose i.p (10 μl /g of 15% glucose). 3. Collect blood at 15, 30, 60, 120 min. 4. Measure the glucose and insulin in all these samples.
Tissue analysis to assess the expression of the vectors and assess the induction of islet neogenesis.
In all these steps the controls that are required to reliably interpret the results include: (1) Empty vector treated diabetic mice (2) non-diabetic mice and (3) non-diabetic pancreas serving as a positive control for the expression of the islet specific hormones and transcription factors.
1. Harvest liver and pancreas at 3 and 6 weeks after treatment. Divide into 2 pieces, the first for snap freezing in liquid nitrogen and storage at -80 °C for RNA and protein extraction, and the second to fix with 10% formalin overnight for immunohistochemistry analysis. 2. Extract RNA by a standard protocol and analyze expression of islet specific hormones and transcriptional factors, along with Ngn3 and Btc to confirm vector expression, in the liver by qRT-PCR using specific primers 9, 10 . 3. Extract insulin and c-peptide from the liver by acid-ethanol extraction method and quantify by a commercial ELISA kit (ultra sensitive Insulin assay, Mercodia, C-peptide ELISA kit, Wako). 4. Perform immunostaining for islet specific hormones (Insulin, Glucagon, PP, SST) along with islet specific transcription factors in paraffin embedded sections 9, 10 . The expression of Ngn3 and Btc can also be confirmed by immunostaining.
Representative Results
We cloned Ngn3 and Btc cDNA into pΔ28 vectors driven by ubiquitous promoter eIF2a (BOS) and generated HDAd-Ngn3 and HDAd-Btc. As shown in Figure 2 , relative HV contamination decreased significantly (implying more vector amplification and less helper amplification) at passage 3. Therefore, we used P3 for subsequent vector production. After the first CsCl discontinuous gradient and ultracentrifugation, we collected the lowest vector band and then collected the opalescent band corresponding to HDAd vector in the second ultracentrifugation ( Figure  3) . The purified HDAd vector had less than 1% of HV contamination ( Figure 4A ) by qPCR and had no helper contamination visible on southern blotting (Figure 4B) , indicating sufficient quality for vector infusion into mice. Further analysis included transgene expression by infection of 116 cells. The mRNA expression levels of Ngn3 and Btc were higher in vector infected cells by over 10,000-fold compared with those in non infected cells ( Figure 5 ).
HDAd-Ngn3 and -Btc were then administered to STZ-induced diabetic mice via tail vein injection with empty vector injected and HDAd-Btc injected diabetic mice serving as negative control. Hyperglycemia was reversed and glucose-stimulated insulin secretion was restored in mice treated with both HDAd-Ngn3 and HDAd-Btc but not in mice treated with single gene vector or control empty vector (Figure 6) . The HDAd-Ngn3-Btc treatment induced islet neogenesis and this was quantitated by assaying total insulin and c-peptide content ( Figure 6E ) with non-diabetic, diabetic empty vector treated mice serving as controls. The presence of c-peptide and insulin in equimolar ratios confirms that the insulin being detected in the liver is indeed being synthesized in the liver. RT-qPCR confirmed that the liver of HDAd-Ngn3-Btc treated mice expressed all the islet-specific hormones and transcription factors 9 . Immunohistochemistry showed insulin positive cells in the liver of mice treated with HDAdNgn3 and HDAd-Btc, but no insulin positive cells were observed in mice treated with control vector (Figure 7) . We also confirmed that there were no residual islets in the pancreas of the Ngn3-Btc treated mice as compared to the numerous islets in non-diabetic pancreas. Vector (Ngn3 and Btc) along with islet specific lineage transcription factor (Pdx-1 and Nkx6.1) expression was also assessed by immunostaining of the liver ( Figure  7) . Figure 1 . Flow chart of gene therapy of diabetic mice using helper-dependent virus system. First, Ngn3 and Btc, in a cassette driven by a ubiquitous BOS promoter, are cloned into HDAd shuttle (pΔ28) vectors. HDAd is produced by several steps including transfection, serial passages of amplification, and a large scale infection followed by vector purification. After characterizing the quality, HDAds are injected intravenously into STZ-induced diabetic mice via tail vein. The effects of treatment are assessed by measuring glucose, body weight, GTT and by analyses of gene expression in the liver. 
Discussion
HDAds have been developed to overcome the weakness of early generation Ads and to harness for gene therapy application. However, technical challenges remain. For example, HDAd requires HV for HDAd's packaging and vector amplification is not as efficient as early generation Ads. HV is a first generation Ad and any contamination of HV compromise the effectiveness of HDAd. Therefore, highly efficient transfection and optimal conditions for each serial passage are critical. Another critical parameter for vector production is which passage (P1-P4) should be used for subsequent passage 5 that is directly used as inoculum for suspension cells. To our experience, the best results are obtained by using the passage by which HDAd vector proportion is dramatically increased in the following passage (P3 in Figure 2 ). The yield of HDAd vectors depends on transgene cassettes. During vector production, both transgenes are expressed because both genes are under ubiquitous promoter. Ngn3 is a transcription factor and Btc is a growth factor, which suggests that HDAd vector expressing transcription factor which may influence cell lineage inhibits vector amplification while that expressing growth hormone helps in vector replication and packaging.
With diabetes assuming epidemic proportions, new approaches to restore b-cell mass are needed. In this report, we describe methods to harness the advantages of HDAd vectors to effect gene transfer of islet lineage-defining transcription factor, Ngn3 along with the islet growth factor, betacellulin to induce islet neogenesis in periportal regions of the liver. To assess the efficacy of this, it is important to choose mice with stable hyperglycemia and ensure that appropriate controls are always included. For this gene transfer experiments, the empty vector treated diabetic mice should always be utilized. In addition, using HDAd-Ngn3 and HDAd-Btc individually treated diabetic mice serves to test the individual contribution of these two genes in islet neogenesis. As our data demonstrates that Ngn3 alone is sufficient to induce islet neogenesis, but the addition of the growth factor, Btc, serves to augment the response leading to robust induction of islet neogenesis. It is also important to
